Sustaining momentum: watch EBITDA margin breadth and CDMO's Q1 cadence
With Q4's exceptional 34% revenue growth and 80% EBITDA surge setting a high bar, Navin Fluorine's Q1 FY27 print will show whether operational gearing is holding. The street expects low-20s margin in Q1—a step down from Q4's 34%—but the real watch: does CDMO keep doubling in a seasonally softer quarter, and is AHF (now live) adding to specialty product mix.
The setup: chasing growth with gearing
NAVINFLUOR's story for FY27 hinges on execution of three plays: the CDMO wing (contract manufacturing for pharma), the new AHF (anhydrous hydrofluoric acid) plant, and R32 refrigerant capacity expansion. Q4 FY26 delivered a tour—₹938 Cr revenue (+34% YoY), operating EBITDA +80% to ₹321 Cr with 34.2% margins. That was the high watermark. Q1 will be messier: seasonal softness in commodity fluorine (lower demand post-summer), but offset by the CDMO growth trajectory and new asset utilization kick-in. What to expect: a quarter that shows either sustained margin expansion (if CDMO and AHF are being put to work) or profit-taking pressure (if growth stalls while prior plants ramp costs). Street expects the former.
~₹800–850 Cr
On-plan for 20–25% growth. Q4 was +34% (exceptional), so modest normalization expected but still solid
~23–26%
Street sees a step-down from Q4's 34% (that was driven by FX and one-time export benefits). Expect a 'boring' 25%, grounded in better utilization than last year
~$20–22 Mn
Q4 grew +61%. If on-track to $100 Mn full-year FY27 (from $40 Mn in FY25), Q1 should show +50–60% growth. This is the real tracker—CDMO is higher margin and the beachhead into specialty
~₹140–160 Cr
Dependent on margin hold and tax rate. Lower than Q4 (which was seasonally strong), but tracking above prior-year Q1 (₹117 Cr, which was +129% YoY)
What a good quarter looks like: Revenue in the ₹800–850 Cr band, EBITDA margin above 25% (showing the gearing from prior capacity spend is real), and CDMO keeping the +50% growth momentum. Earmarks: AHF (live now) contribution to gross margin, R32 utilization ramping into mid-year. What a weak quarter looks like: Revenue below ₹780 Cr (demand stumble), margin squeeze below 22% (cost inflation, lower CDMO mix), or CDMO growth stalling below +40% (suggests the new customer pipeline is soft). Either would raise questions about FY27 guidance sustainability.
Is the company tracking guidance?
Full-year FY27 expectations are clear from analyst consensus: ₹3,600–3,800 Cr revenue (27% CAGR vs FY25), 34% EBITDA CAGR, margin in 23–26% range. Q4 FY26 was ₹938 Cr revenue, so Q1–Q3 need to average ~₹870 Cr to hit the midpoint of FY27 guidance. On current form (Q1 FY26 was ₹725 Cr, Q4 was ₹938 Cr), expecting Q1 FY27 in the ₹800–850 band is reasonable. The risk: if commodity prices (fluorine HCFCs, HFCs) roll over or if any customer (e.g., Chemours project, expected to finish by end-June) delays payment or recognition, Q1 could miss low-ball. Odds favor on-plan, but the tape is still thin—watch for any guidance revisions or headwinds flagged on the call.
Street positioning and the consensus
ICICI Securities (one of the active houses on the name) has pegged a target of ₹7,250, based on 26x FY28E EBITDA, implying they're betting on the CDMO and new capacity story to de-rate commodity fluorine exposure. The consensus has nudged target lower slightly in recent months as FY27 revenue growth assumptions have hardened from 18.7% to ~19%, a sign that the Street is getting more disciplined on the pace but still backing the thesis.
Since last quarter: the events log
1 · DRDO partnership (Jul 30): Sodium Borohydride for defence
Navin Fluorine signed an agreement with DRDO to manufacture Sodium Borohydride in bulk, indigenous supply for Indian defence. This is symbolic of strategic pivot into high-value, regulated chemicals; margins unproven but flags willingness to service non-commodity end-markets. Not material to Q1 numbers but a thesis tailwind.
2 · Capex infusions (Jul 27, Jun 5): ₹3.63 Cr + ₹5.5 Cr SPVs for power
Via Compulsory Convertible Debentures in subsidiary Pro-Zeal Green Power. Signals confidence in utilization and cost-of-production play (renewable power to offset inflation). Operational but routine; no P&L impact Q1.
3 · Dividend and AGM (Apr 29, Aug 6): ₹8.60 final for FY26, AGM on Aug 6
Final dividend approved; AGM same day as results release (Aug 6). Routine but tight calendar—any guidance revision would come via the call on Aug 5, leaving little time for market digestion before shareholder vote. Not a risk, but note the flow.
4 · SBI MF stake build (Jul 6): 5.01% acquired
SBI Mutual Fund acquired 47,160 shares (5% holding). Domestic MF rotation into the name; a 'story' confirmation from institutional money. No voting impact but signals conviction on FY27 execution.
5 · LIC stake reduction (Apr 17): 6.98% → 4.97%
LIC trimmed holdings by ~2pp in April. Likely profit-taking on the run-up post Q4; not a red flag but note that long-only positions are being lightened. Institutional churn is normal in a +60% stock off the low.
What to watch on result day (Aug 5, 6:30 PM IST)
1 · CDMO revenue cadence: Is +50–60% growth sustainable?
Q4 was +61%. If Q1 dips to +30–40%, it's not a miss but signals customer concentration risk or project lumpiness. Mgmt should break out CDMO revenue explicitly; if they don't, ask. This is the crux of the FY27 thesis.
2 · AHF plant: utilization % and margin contribution in Q1
Now live. Even if not at nameplate, any quantifiable ramp (e.g., 'operating at 60% utilization' or 'added ₹X margin in Q1') validates the capex ROI story. Vague language = caution.
3 · Chemours project: status and Q2–Q3 revenue recognition
Expected finish by end-June or early-July. Q1 contribution unclear; check if project revenues are recognized and if there's a lumpiness risk in Q2.
4 · EBITDA margin progression: normalized levels and FY27 guide reiteration
Q4's 34% was exceptional (FX benefit, product mix). Mgmt should walk the 23–26% range for FY27 and explain driver (mix, leverage, pricing). If margin outlook is narrowed down or revised, that moves the needle on FY27 profit.
5 · R32 expansion timeline: Q3 FY27 still on track?
Critical for H2 FY27 growth. Any delay flags execution risk. Ask specifically on capex spend-down and commissioning dates.
Navin Fluorine goes into Q1 FY27 with a strong run-rate and clear structural tailwinds (CDMO, AHF, R32). The Street has backed the stock to ₹7,316+ on that thesis. The bar for Q1 is simply on-plan: ₹800–850 Cr revenue, EBITDA margin above 25%, CDMO growth above 50%. Anything materially below that resets the FY27 growth narrative and invites multiple compression. But on the evidence—Q4 momentum, two new plants in the mix, a healthy order book—the base case is that management delivers and the stock holds its premium. The real test will be margin breadth: can they sustain 25%+ even as volumes ramp? That's the thesis. Watch the call carefully; the questions matter as much as the numbers.
Informational and educational content only. Not investment advice.